Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis
Early outpatient treatment with nirmatrelvir/ritonavir may mitigate the risk of developing several domains of long COVID, though its benefits are not uniform across all symptom categories.
Authors
- Timotius Ivan Hariyanto
- Akhil Deepak Vatvani
- Arif Nur Muhammad Ansori (ORCID: https://orcid.org/0000-0002-1279-3904)
- C. Cucunawangsih
Institutions
- Pelita Harapan University (ID)
- Universitas Airlangga (ID)
- VIR Biotechnology (United States) (US)
- Universitas Dr. Soetomo (ID)
Publication Details
- Journal
- Expert Review of Anti-infective Therapy
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1080/14787210.2026.2636175
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 0.00